Skip to main content
. Author manuscript; available in PMC: 2014 Sep 16.
Published in final edited form as: Leuk Res. 2010 Feb 19;34(7):925–931. doi: 10.1016/j.leukres.2010.01.020

Figure 5.

Figure 5

Figure 5

Panel a: Active but not heat inactivated catalase, protects against As2O3 and ascorbic acid mediated cytotoxicity in primary CLL B cells. Purified B-lymphocytes from CLL patients (1×106/ml media) were pretreated with 500 units of active catalase or heat inactivated catalase (HI) for 30 minutes prior to addition of arsenic trioxide [ATO] (1μM) and ascorbic acid (1mM). The cells were stained with Annexin-V-FITC and propidium iodide and the cells were analyzed by flow cytometry after 24 hours. The data shown represent % Annexin-V-/PI- viable cells ± SD that are normalized to media control. (n=6; p<0.05).

Panel b: Catalase inhibitor aminotriazole enhances the cytotoxicity of As2O3 and ascorbic acid towards primary CLL B cells. Purified B-lymphocytes from CLL patients (1×106/ml media) were pretreated with 100mM aminotriazole for 30 minutes prior to addition of arsenic trioxide [ATO] (1μM) and ascorbic acid (1mM). The cells were stained with Annexin-V-FITC and propidium iodide and the cells were analyzed by flow cytometry after 24 hours. The data shown represent % Annexin-V-/PI-viable cells ± SD that are normalized to media control. (n=6; p<0.05).